Knight Therapeutics Posts Q2 Financial Report

Knight Therapeutics (TSX:GUD) released their financial returns for the second quarter of 2017.
As quoted in the press release:

Q2-2017 Highlights

• Revenues reached $2,840, an increase of $1,345 or 119% over the same period in prior year
• Cash flows from operations were $3,371, an increase of $289 or 9% over the same period in prior year
• Submitted Probuphine™ for approval by Health Canada
• Issued additional secured loan tranches of US$1,807 to 60 Degree Pharmaceuticals (“60P”)
• Contributed capital of $6,190 and received distributions of $1,222 from strategic fund investments

Subsequent Events

• Realized gain of $1,457 on disposal of common shares of Merus upon the close of its acquisition by Norgine B.V.
• Medison Biotech (1995) Ltd.’s (“Medison”) board of directors declared and approved dividends of $2,466 [ILS7,068]
• Issued an additional secured loan of US$10,000 to Synergy CHC Corp. (“Synergy”)

“This past quarter was highlighted by continued revenue growth, as well as the submission of Probuphine™ for approval by Health Canada, bringing a novel product one step closer to improving the health of Canadians,” said Jonathan Ross Goodman, CEO of Knight. “In the quarters ahead, we will continue to be focused on advancing our pipeline and capitalizing on GUD opportunities for growth.”

Click here to read the full press release.

Source: www.marketwired.com